No Benefit of Covered vs Uncovered Self-Expandable Metal Stents in Patients With Malignant Distal Biliary Obstruction: A Meta-analysis

详细信息    查看全文

• 作者：Majid A. Almadi^? ; ^&Dagger ; ; Alan N. Barkun^? ; ^§ ; ; ^{alan.barkun@muhc.mcgill.ca} ; Myriam Martel^?
• 关键词：Treatment ; Surgery ; Plastic Biliary Stents ; Comparison
• 刊名：Clinical Gastroenterology and Hepatology
• 出版年：2013
• 出版时间：January, 2013
• 年：2013
• 卷：11
• 期：1
• 页码：27-37.e1
• 全文大小：1282 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Background & Aims

Self-expandable metal stents (SEMS) are used in patients with malignant distal biliary obstruction; trials that compared covered and uncovered SEMS reported different results because of heterogeneous designs and patient populations. These studies compared patency of uncovered SEMS and covered SEMS, along with rates of pancreatitis, cholecystitis, cholangitis, SEMS migration, bleeding, perforation, and recurrent biliary obstruction.

Methods

We performed a meta-analysis to compare the effects of covered and uncovered SEMS in patients with malignant distal biliary obstruction. We identified randomized controlled trials by using a literature search from 1980 through March 2012. We evaluated data from 5 full articles and 4 abstracts, comprising 1061 patients, and assessed statistical heterogeneity and publication bias.

Results

The weighted mean difference in the stent patency duration could only be calculated on the basis of 2 studies, but it was 67.9 days longer for covered SEMS than for uncovered SEMS (95 % confidence interval [CI], 60.3-75.5). A summary analysis of data from 4 trials demonstrated no differences in patency of covered vs uncovered SEMS after 6 months (odds ratio [OR], 1.82; 95 % CI, 0.62-5.25) or 12 months (OR, 1.25; 95 % CI, 0.65-2.39). There were also no differences in the rates of pancreatitis, cholecystitis, perforation, bleeding, or cholangitis; length of hospital stay; or number of recurrent biliary obstructions. However, covered SEMS had a higher migration rate (OR, 7.13; 95 % CI, 2.29-22.21). Patients with covered SEMS had a lower rate of tumor ingrowth (OR, 0.19; 95 % CI, 0.07-0.55) but a higher rate of tumor overgrowth (OR, 1.88; 95 % CI, 1.02-3.45). No summary calculations could be completed to confidently assess patient survival.

Conclusions

The use of covered SEMS, compared with uncovered SEMS, in patients with distal malignant biliary obstruction is of unclear benefit; covered SEMS have a higher rate of migration and do not appear to have longer patency.